In this retrospective single-center cohort of patients with non-traumatic spontaneous SAH, the early use of ICP/PbtO2 guided therapy compared to patients that received no therapy or ICP only guide therapy was not associated with an improved outcome. Only in patients requiring a therapy driven by MMM (i.e. ICP or combined ICP/PbtO2), PbtO2-guided therapy was associated with a lower risk of UO than ICP-guided therapy. Brain hypoxia was independently associated with a poor neurological outcome. In patients monitored with PbtO2 catheters, PbtO2 guided therapy was associated with a lesser risk of death.
MMM has been widely advocated to assess poor grade neurocritical patients, since the severity of the initial injury or the concomitant use of sedation and/or neuromuscular blockade significantly reduce the reliability of clinical examination to detect neurologic deterioration or tissue hypoxia.14 PbtO2 monitoring provide focal but clinically relevant information on tissue oxygenation and, if adequately interpreted and included into a therapeutic protocol, could act as an early trigger to initiate therapies even in the presence of normal ICP values.17 This is even more relevant in SAH patients, as sustained and severe increase of ICP are less frequent than in TBI patients and tissue hypoxia can be driven by other mechanisms than cerebral swelling, such as diffuse hypoperfusion or delayed vasoconstriction.17
Brain oxygen values reflect an equilibrium between oxygen delivery (i.e. cerebral blood flow, hemoglobin and arterial oxygenation), consumption (i.e. brain metabolism, mitochondria and body temperature) and extraction (microcirculation and blood-brain barrier).38,39 In SAH patients, low PbtO2 has been associated with different pathologic pathways, such as low cerebral blood flow,30,40 lung injury with hypoxemia22,41 and/or anemia.42 As such, strategies aiming at increasing cerebral blood flow, using high inspired oxygen fraction on the ventilator or prescribing red blood cell transfusion can increases PbtO2 levels in some of these patients.44,43 However, low PbtO2 levels do not necessarily represent tissue ischemia38 and some studies failed to show an association between low PbtO2 and unfavorable outcomes.44,45 In our study, episodes of PbtO2 < 20 mmHg and < 10 mmHg were associated with unfavorable neurological outcome but not mortality, perhaps because PbtO2 guided therapy successfully improved survival in the cohort of patients monitored with combined ICP/PbtO2. Future studies should evaluate in larger cohorts the optimal threshold of PbtO2 to predict poor neurological outcome and mortality and therefore optimize therapies in SAH patients. The integration of ICP/PbtO2 monitoring with other tools (i.e. electroencephalography, cerebral microdialysis) should therefore be considered as a useful MMM approach to precisely define the pathophysiology of brain injury and individualize clinical management in SAH patients, although additional data are necessary to understand its role on modifying patients’ outcome.14,46
In TBI patients, Okonkwo et al. 26 showed that the use of PbtO2 guided therapy using a specific and complex protocol reduced the burden of brain hypoxia when compared to patients that underwent ICP guided therapy only. Furthermore, two meta-analysis reported that ICP/PbtO2 guided therapy was associated with improved neurologic outcome, when compared with standard ICP-guided therapy47,48; although large randomized trials in TBI patients are currently ongoing to provide more robust evidence. In our study, the burden of brain hypoxia remains relatively high despite of protocolized PbtO2-guided therapy. In another study, Rass et al. 2019 44 also showed similar results: 81% of SAH patients included in two experienced centers had at least one episode of brain hypoxia (i.e.PbtO2 < 20mmHg). This could explain why we could not find an association of PbtO2-guided therapy compared to no therapy and/or ICP-guided therapy with an improvement in neurological outcome, since the proposed treatment may not be enough to reverse tissue hypoxia, even in the presence of protocolized strategies. Moreover, we lack robust data showing which intervention (i.e. raising blood pressure, transfusions, changes in PaCO2 or body temperature etc.) is the most effective to correct brain hypoxia in SAH patients. Also, as brain hypoxia can occur either in the early phase but also after several days since admission because of DCI, the lack of adequate evidence supporting effective therapeutic strategies to treat DCI would also limit the effectiveness of PbtO2-guided therapies in this setting.
Some patients had normal ICP and PbtO2 values and required no intervention; moreover, as the monitoring itself cannot improve outcome alone since the decision to treat is ultimately at the clinician’s discretions we performed an additional analysis including only those patients where an intervention was undertaken, either guided by ICP alone or by ICP/PbtO2. In this subgroup of patients, PbtO2-guided therapy was associated with a favorable neurological outcome when compared to ICP-guided therapy. In a before/after study, Veldeman et al. showed that the implementation of PbtO2 and microdialysis monitoring in poor grade SAH patients was associated with an earlier detection of DCI and a significant reduction in the occurrence of UO, from 60–46%.49 In another before/after study including good grade SAH patients with secondary deterioration, the introduction of invasive neuromonitoring (PbtO2 and microdialysis) was associated a significant reduction of silent cerebral infarctions, although no significant effects on neurological outcome was observed.50 However, as the introduction of neuromonitoring could also been associated with other significant changes in diagnostic procedure and patients’ management (i.e. before and after study), it is difficult to conclude the effectiveness of invasive neuromonitoring on patients’ outcome from these studies.
Our study has some limitations. First due to its retrospective design, some deviations from protocolized care or decisions to tolerate quite low PbtO2 values (i.e. 15–20 mmHg) in case of improvement of clinical status and/or awakening could not be adequately addressed. Second, the number of patients receiving PbtO2 monitoring was relatively limited, which may have reduced the power for future statistical adjustment to assess smaller effects of PbtO2 monitoring on patients’ outcome. Third, as this cohort reflected the experience of a single center, generalizability of our findings might be limited. Finally, we did not specifically report all single therapeutic interventions and their effects on PbtO2 values over time.